Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.
Mcgill University Health center, Montreal, Quebec, Canada
GSK Investigational Site, Zaandam, Netherlands
Columbia University Medical Center, New York, New York, United States
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
Medical University of South Carolina, Charleston, South Carolina, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.